Benefit of primary angioplasty in patients presenting late with ST segment elevation and acute myocardial infarction  by French, W.J. & Sada, M.J.
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M~thods: We evaluated the outcome for patients who pro~entod in Killip 
II and III in the GUSTO lib substudy, the largest randomized trial of direct 
PTCA vemu': thmmbolysis 
Results: This CHF group w~s older (66.6 ym vs 69,,0 yrs, p ~ 0001 ) end 
with higher mine of pnor angina (51.6% vs 386%, p = 0,016), prior CHF 
(5,3% vS 1,3%, 1~ < 001), and GOPD (8,G% vs 12%, p - 0,00t) than the 
Killip I gn~p, 
~ ;  A ~  this i$ the I ~  humber o! ipatteht~, with CHF ran~ 
domized to PTCA v~ thrombOSiS, the ~n'~le si;~ is small, The~e findings, 
whi~ 1101 stattM¢ally s~nif¢ant, raise_ the IgOtL~ntia! of a~ gro~ter benefit for 
PTCA at 30 d,i~ys and O month~ in patients presenting in Ki!lip classes II and 
lit compticat~_ an AML A I~ ,  Irml would be needed to resolve this iSSUe, 
~nd to inve~ti~to a~ potential role for adjgn~rve therapy. 
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~ IBone~ of !~immy Ang!opla!~/in IP~tkmts 
.~m..ling ~ W~h ST Segment Zk.mtio~ and 
ACuAe MyO¢#!'dLM far¢tk~ 
WJ, French, M,J, S~,  Fr~ pt~e Na~l  ~ et ~n~zt  Inaction 
(NRMt-2~ Ireves~tc~S: H a ~  Medial Center, Tonance~ CaMom~ 
Primary PTCA (P  PTCA) is used m lmaWnem at ~atmnts with acute myocar, 
~al infarcteo~, but Its effective~=se in late presenters has not been defined. 
3 ,~ Pts were evahJated with ST ele~atto~ who presented more than 12 
his afte~ s~ onset but ethan=so were el~3ble fo~ thrembo~ therapy (Try), 
and were e~ro~;J m NRMI-2 between 1994 and 1996. PtS in ~hock or who 
~ TTx were exclu~,~. TI~ mvasn~e group ~ 568 pts ~he unc~r- 
~nt  Ca~ within 6 I'ers o! ~ with 80%, hav~cJ 1~ PTCA. The med/(~! 
merapy (MTX) group included IN%. m 2.g82 I~S. The mvastve group were 
yoong~r (60.9 vs 6S.7 yre), more t'~=ty ma~e (66.2 vs 59.6%) w~ a 
of PTCA (8.1 vs 4.3%), but hess ~kety to have had CHF (3.7 vs 8.1%) or 
CABG (4.6 vs 8(P~, all p < 0.001). ~ pts m the invas~ve group were 
more likely tO be in K~p class I (82.8 v'S 7"7.7%, p < 0.001), other pmsentir~ 
Characto~ were s~mdar to pta m ~e ~,TTX group. The ewasp~ gro~p were 
more likely to receeve belPano (93.3 vs 81 5%). aspmn (896 ve 62.2%), and 
IV beta blockers (19.1 trS 142%, ~ p < 0-001) wdhm 24 hm of ad~issmn. 
In-has.tel me~tatrty m the mvasnm group was 2.8%, compared with 7.8% m 
the MIX  geoup (p < 0001). After multivariate ad[ustn~nt, the i ~  group 
were less likely to die than those in the MI"X grot~ (odds rst~o 0.47. 95% 
cord derto~ interval 027 to 0.82). 
C,~nctus~q: Pts with acute myocar~al infarction who presented more than 
1~ hours after s~om onset appear to benefit from primary ang~oplasty 
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~ Improving Outcomes in Undergoing Patients 
Primary Angiopiasty for Acute Myocardial Infarction: 
..~:=.,d Data From t~= National Registry of Myocardial 
Infarction 2
A.J. l~etenbmnn, N. Every. SR. Pirzeda, W.J. French. W.D. Weaver, 
W.J. Rogers. Washington ~ts~p/  School of Medicine, St. Louts, MO, USA 
Although there is increasing use of angmplasty (PTCA) for acute rnyocar0iai 
infarction (MI). little data about trends are available, Nalwnal Registry of 
Myocardial InfarcOon 2. an ongoing study, collects data that can be used to 
assess trends for this reperfusion modality. Data from rwe 6 month periods 
from July 1994 through December 1996 were analyzed. 
Of over 100,000 patients with ST elevabon recennng reperfirsi0n, use of 
primary PTCA increased from 9.6% to 12.3%. There were no differences in 
mean age or proportion over 75 yrs, male, antedor MI. or w~th Shock. All 
trends in the table are statistically significant. Mean door to balloon time and 
in-hospital mortality have decreased, although more patients are TTMI "not 
Im~ dsk." The use of stents and/or antiplatelet herapy ether than aSpinn has 
increased, while repeat PTCA has decreased. 
Study Period 1 2 3 4 5 
Pnmary PTCA (%) 9 6 9 9 11 4 120 12 3 
Mean Door to Balloon ~,min) 179 164 160 159 157 
TIMI e0t tow nsk (%) 44 1 448 47 5 471 499 
Mortality (%) 7.4 75 6 8 6.3 
Non ASA Antnplatelet (%) 3.6 42 72 16.2 25 7 
Stent (%) 6.6 8.6 12.4 209 248 
Second PTCA (%) 17.9 14.1 12.2 12 7 10.7 
These unaJjusted trend data indicate increased use of priman] PTCA. 
earlier therapy, and improving clinical outcomes. 
[~  Randomized Trials of Antlhypertenslve 
Agents 
Tuesday, March 31, 1998, 2:00 pm -3:30 p,m, 
Georgia World Congress Center, Room 365W 
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~ Blood Pmuum Low~lng in Pltlentt With 
~febfovnru!lr Oifl~l#: Flnullo of t l~ 
R=ndomlmd I=ott-Mmlw Ant~s l~ 
~ t  Study (~Ts) 
L, IJu, L Gong, Ji Ggang W~ng, For ~ PATS Invem~fom; Card~ova~:utat 
tnstrtute and F~i  ~a l ,  Bet~,  Chm~ 
Background: The raedOrm~e~ Po~t-atroke Anlihype~msNe Troa~tmef~ Sludy 
(PATS) aimed at detanlnmmg whether antlhypeflenslve (~g ~ COuld 
re~ the .sk of stroke incidence and ethel caKliovascutar comptw.,atiorm in 
patrenfs wllh a history 0f stroke or lm~ent  iscl~n~ sttack (TIA), 
Mett~od~: A tolal el ~5 pa~tmnl~ were falld~mzed (2B41 Io ~ treat. 
merit, took 2.5 mg indapam;cl~ per day; 2824 t0 placebo look (me taDlet at 
placebo), Age (±SD) averaged 60 +_ 6 yearn, 2f~-~o were women, and 64% 
were is¢fiem=c, Mea~ BP was 154/93 mmHg, In 913 (16%) subiects BP was 
below 1 ~  mmHg 
R~."  Average follOW-Up ap~roximarod to 2 ~P.am. The three-year aver- 
age BP was 149/89 mmHg for the placebo group and 14,4~7 mm Hg fo~ the 
indapan,~cle group, mspectwety. The three-year fatal and nonfatal stroke incl, 
¢lence rate was 12.1% for placebo and82% for ~ .  The relatwe ns*~ 
~ hazards regressmn anatyam was 0.69 (95% Cl: 0.57~.85, 
P < 0.001). In g13 normot~ ~ lhe three-year cumulative stroke 
inc1OenCe rate was B.7% for i'n~apamide growls and 49% for placebo group 
Relative risk for all cause mortaJity was 0.92 (95% CI: 0.74-I .14, P = 0.45) 
malt sul~ecta. 
Conc/us~o~ In post-stroke pahents with or w~theut h~gh I~lood pressure, 
BP reductmn of 5/2 mmHg with 2.5 mg indaparn~e per day reduced the fatal 
and nonfatal stroke incidence by 31%. 
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~ Effect  o f  Ramipf l l  A f te r  Myocardia l  Acute In farct ion  
in Pat ients W'dlt Ar t l~ml  Hyper tens ion  
CS.  Sparglas, A.S. Hdii, S+G. Ball. Inshlufe for Cardiovascular Research, 
~rs rZy  ot Leeds, UK 
Background" After myocardial |nfarctlon (MI), patients with a history of aria- 
nat hypertensxon (AH) have a worse prognosis than that of normotons~ves. 
Ang~otensm coxwemng enzyme (ACE) mhibdlon post MI substantially im- 
proves survival in high nsk populahons. This study evaluates the influence o! 
a ~story of ,~H on the efficacy of ACE inhibition post MI. 
Meff/oGs: We ~ e t y  analyzed dela from the AIRE study (random- 
ized. p l~t ro t led  trial ot ramipfit m 2006 post MI patients with cltnma! 
e~clence o! hear faiture-HF). At baseline, 28% o! the pahents had a histoW 
of" AH. We exammecl the effect of rarn~pnl on clm~al outcomes according to 
whether or not a history of AH was p,esent. To adjust for baseline chnrcal 
differerces, 16 vanables were ~imultaneously entered in a mufflvanete Cox 
regression model. 
Results: Treatment with ramtpnt resulted in a significant reduction in the 
risk of all-cause modality in the llypertensive patients (32%, CI 1% to 54%, p 
= 004) but not m the normotensNe group (14%, CI - 11 to 34%, NS). There 
was also an associated trend toward lower HF- morbidity in the hypertensives 
(31%, Ct -4  to 46%. p = 0.07) but not in the normotens~ves (5%, CI -26 to 
28%, NS). 
Conclusion: Our data indicate that ACE inhibition, in patvents with clinmal 
evidence of HF post MI, is of pa~cular benefit to those w~th a history of AH 
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~ A  Study on Optimal Treatment f l~rmt~SS H 
St,a;~=gles for Hypertension and CAD: Pilot PhaSe 
Data From the INternational VErapamll-trandoiapril 
STudy (INVEST) 
C.J. Pepine. M. Conlon. E. Hancfoerg-Tbermond, R G. Marks. 
R. Cooper-DeHoff. H Robert Kelb. University of Florida, Gainestfilte. 
Florida, USA 
The INVEST is a trial to assess whether a calcium a~agonist treatment 
strategy is equivalent o a noncalciurn antagonist strategy (JNC V) to prevent 
adverse outcomes in 27.000 patients with hypertension and CAD. Patients 
are being enrolled at 1,500 primary care sites using a novel electromc sys. 
tern for direct on-screen data entry, randomization and drug distnbut~on from 
